Can you take Papaverine with Revuforj?
1 drug interaction and 12 additional warnings found for the following 2 drugs:
- papaverine
- Revuforj (revumenib)
Drug interactions
Major drug interactions
Major:
papaverine revumenib
Applies to: papaverine and Revuforj (revumenib)
Before getting treatment with papaverine, let your doctor know if you are currently using revumenib.
Combining these medications can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
papaverine Food/Lifestyle
Applies to: papaverine
The following interaction applies only when papaverine is used as part of a combination containing both papaverine and phentolamine that is injected into the penis.
Smoking tobacco before using papaverine to achieve an erection may reduce the effect of the treatment.
Avoid smoking for at least 1 hour before the injection with papaverine. If the treatment does not work as expected, do not repeat the injection or increase your dose without first talking to your doctor.
Talk to a healthcare professional if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs.
Moderate:
revumenib Food/Lifestyle
Applies to: Revuforj (revumenib)
High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).
Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.
Symptoms of differentiation syndrome include:
- fever
- cough
- shortness of breath
- severe headache
- confusion
- dizziness
- rapid weight gain
- swelling
- decreased urination
You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.
The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.
Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate:
papaverine Alcohol (Ethanol)
Applies to: papaverine
Ethanol and papaverine may have additive effects in lowering your blood pressure.
You may experience headache, dizziness, lightheadedness, fainting, or changes in pulse or heart rate, especially when treatment is started, the dose is changed, or treatment is restarted.
Tell your doctor promptly if these symptoms occur and seek urgent medical help if you faint or have severe dizziness.
Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
9 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Liver Disease, and Long QT Syndrome.
Arrhythmia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Glaucoma/Intraocular Hypertension
Moderate:
papaverine
Papaverine has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
The use of papaverine derivatives has been associated with an increase in intraocular pressure. Therapy with papaverine derivatives should be administered cautiously in patients with glaucoma.
Heart Block
Major:
papaverine
Papaverine has a major potential interaction with Heart Block.
The use of papaverine and papaverine derivatives is contraindicated in patients with complete AV heart block. When conduction is depressed, these agents can induce transient ectopic rhythms of ventricular origin, either premature beats or paroxysmal tachycardia. Therapy with these agents should be administered cautiously in patients with conduction disturbances, including sinus bradyarrhythmia and partial or first-degree AV block.
Heart Failure
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Heart Failure.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Hypokalemia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Liver Disease
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Liver Disease.
Revumenib has not been studied in patients with severe liver or renal impairment.
Long QT Syndrome
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Magnesium Imbalance
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Renal Dysfunction
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.
Revumenib has not been studied in patients with severe liver or renal impairment.
Report options
More resources
papaverine
A total of 402 drugs are known to interact with papaverine.
- Papaverine is in the drug class peripheral vasodilators.
- Papaverine is used to treat Vasospasm.
Revuforj
A total of 583 drugs are known to interact with Revuforj.
- Revuforj is in the drug class miscellaneous antineoplastics.
- Revuforj is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.